Price comparison of the 10 most expensive drugs as of 2018

Per-year list price of the top ten most expensive drugs worldwide as of 2018*

by Matej Mikulic, last edited Aug 9, 2019
Price comparison of the 10 most expensive drugs as of 2018 The number one most expensive drug, as of 2018, was Glybera or alipogene tiparvovec with a list price of around 1.2 million U.S. dollars per year. Ravicti was ranked the second expensive drug, used in the long-term treatment of urea cycle disorders. Ravicti is marketed by Horizon Pharma, a former U.S.-based but now Irish-based pharmaceutical company. The most costly drugs worldwide based on wholesale acquisition cost (list price) are mostly orphan drugs for rare diseases.
What are orphan drugs?

Orphan drugs are pharmaceutical products for the treatment of so-called rare diseases. These are diseases with a very low prevalence within a population. Thus, it is not too appealing for companies to invest into R&D for drugs, which they potentially could sell only to a small number of patients. However, because persons afflicted by rare diseases should have the same right for care and treatment as persons with more common diseases, specific regulations were introduced over time. In 1983, the Orphan Drug Act was signed in the United States, for example.

The impact of the Orphan Drug Act

The Orphan Drug Act applies certain incentives for pharmaceutical companies to develop and market orphan drugs. This includes, for example, tax credits on clinical research, accelerated administrative procedures, and a 7-year market exclusivity after approval. These and other benefits significantly changed the level of interest in rare disease treatments. Given the fact that there are around 7,000 rare and ultra-rare diseases, drug manufacturers are increasingly entering this market with large potential. It becomes especially profitable when an already existing drug for common diseases also shows effects on a rare disease, or when an orphan drug emerges to be effective for other, more common diseases. In such cases, the orphan status of the drug helps companies to extend market exclusivity and add higher price tags, causing some critics to claim that the industry is gaming the system.
Show more

Per-year list price of the top ten most expensive drugs worldwide as of 2018*

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Orphan drugs
Orphan drugs

All Information
in one Presentation

Orphan drugs

Everything On "Orphan drugs" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

I think of Statista as Google for researchers. Statista provides you with the information you search for right away.
Dr. Horst Stipp

Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation

Statistics on "Orphan drugs"
  • Market overview
The most important statistics
  • Companies
  • Products
  • Research and development
  • Rare diseases
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.